Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2011 07:00 ET | Source: Zogenix

Zogenix to Present at Two Upcoming Conferences

SAN DIEGO, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
November 10, 2011 16:05 ET | Source: Zogenix

Zogenix Reports Third Quarter 2011 Financial Results

Zogenix Continued Growth of SUMAVEL DosePro Prescriptions and Reported Positive Phase 3 Efficacy Results on Zohydro Conference Call and Webcast Today, November 10th, at 4:30 p.m....
November 04, 2011 16:30 ET | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results

SAN DIEGO, Nov. 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
October 12, 2011 07:30 ET | Source: Zogenix

Zogenix to Host Investor Meeting on October 13, 2011

SAN DIEGO, Oct. 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
September 30, 2011 07:30 ET | Source: Zogenix

Zogenix Achieves Zohydro(TM) Long-Term Safety Database for NDA

SAN DIEGO, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
September 19, 2011 16:30 ET | Source: Zogenix

Zogenix to Present at UBS 2011 Global Life Sciences Conference

SAN DIEGO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
September 16, 2011 07:30 ET | Source: Zogenix

Zogenix Prices Public Offering of Common Stock

SAN DIEGO, Sept. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the pricing of its underwritten public offering of 30,000,000 shares of its common stock at $2.00 per share,...
August 24, 2011 07:30 ET | Source: Zogenix

Zogenix Files Registration Statement for Proposed Follow-On Offering

SAN DIEGO, Aug. 24, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC)...
August 17, 2011 07:30 ET | Source: Zogenix

Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint

First Extended-Release Hydrocodone Product Without Acetaminophen NDA Submission Expected by Early 2012 Conference Call and Webcast Today, August 17th, at 8:30 a.m. ET SAN DIEGO, Aug. 17, 2011...
August 16, 2011 17:18 ET | Source: Zogenix

Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain

SAN DIEGO, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...